• Global pharma firms interested in local startup's new glaucoma treatment​

    We are pleased to share that the local biotech startup Peregrine Ophthalmic founded by NTU Provost Professor Freddy Boey, MSE Chair Professor Subbu Venkatraman and Adjunct Associate Professor Tina Wong have been featured in The Business Times. Please click here for more details.

  • President’s Technology Awards 2014

    We would like to extend our warmest congratulations to Professor Subbu Venkatraman, Professor Freddy Boey and Adjunct Associate Professor Tina Wong for receiving ​the 2014 President's Technology Award. The prestigious award was presented to t​he team for their innovative application of nanostructures and novel drug delivery approach to combat blindness from glaucoma. Please click here for more details.

  • Open research positions for applications

    The School of Materials Science and Engineering ( is seeking to recruit research staff to participate in a multi-disciplinary research programme on Ocular and Cardiovascular Drug Delivery. The programme involves interaction of biologists, chemists, medical doctors, biomedical engineers and materials scientists. There is world-wide interaction among collaborators as part of this programme, with the possibility of exchange visits. Several spin-off companies are anticipated to be formed from this research programme, ensuring continued employment opportunities. Please click here for more details.

  • Open Nanomedicine position for application

    The NTU-Northwestern Institute for Nanomedicine is seeking a qualified individual to be a research coordinator for various projects within the Institute. Prior administrative experience with project management including budget management is required. Familiarity with Nanomedicine is highly desirable. Some project participation is also anticipated. Please click here for more details.

  • PhD Programme in Future Healthcare @ NITHM

    The Interdisciplinary Graduate School (IGS) Thematic PhD Research Programmes in Future Healthcare at Nanyang Institute of Technology in Health and Medicine (NITHM) offer Doctor of Philosophy in the following:

    • Biodegradable scaffold with nano-materials for treating heart disease (Nanomedicine)
    • Bioactivity and controlled release studies of proteins in nanocarriers (Nanomedicine)
    • Fundamental studies of sustained release from nanocarriers (Nanomedicine)
    • Topical delivery of systemic therapeutic agents for use in skin inflammatory disorders (Skin Research)

    Please click here for more information on graduate programmes and application requirements for the latest intake.

  • Amaranth Medical obtains Series C funding

    Amaranth Medical, the company founded by Professors Freddy Boey and Subbu Venkatraman, has received Series C funding. The company, which manufactures fully bio-absorbable stents, secured equity investment from Boston Scientific, a global medical devices manufacturer, and the leader in coronary stenting.

    Amaranth's core technology involves proprietary methods of creating bio-absorbable polymeric stents which offer a number of benefits over the metal stents currently in use. Amaranth’s stents are self-expanding at body temperature, fully biodegradable, biocompatible and possesses the best mechanical attributes of any biodegradable stent currently being tested or approved.

    Reported in:
    - The Business Times

  • NTU establishes new $60 million research institute in nanomedicine

    Nanyang Technological University (NTU) is setting up a Nanomedicine Institute @ NTU. This is a $60 million research institute for nanomedicine - the first of its kind in South-east Asia. The university wide Nanomedicine Institute @ NTU will have research facilities in both NTU’s Yunnan Garden campus and Novena campus. It will bring together NTU’s key nanotechnology-related projects and experts, across its engineering and science schools, including NTU’s new medical school, the Lee Kong Chian School of Medicine.

    The new Institute will have Professor Subbu Venkatraman, as its Director. Professor Chad Mirkin, a celebrated nanotechnology expert, from Northwestern University will serve as Chairman of the institute's advisory committee.

    The institute's research will focus on four key areas: diabetes, cardiovascular diseases, ophthalmology and skin therapeutics. Nanomedicine is a relatively new discipline that combines nanomaterials-based detection and treatment of diseases. Among the technologies that are included in the field of Nanomedicine are: nanocarrier-based drug and gene delivery; in vivo imaging using nanoparticles; in vitro diagnostics based on nanomaterials; bioactive implants and nanotoxicology. Nanomedicine aims to explore solutions to medical problems using approaches that use nanotechnology. The working hypothesis is that the nanotechnological solutions are superior to micro or macro technologies for these specific problems.

    Reported in:
    - Nanowerk News
    - News-Medical.Net
    - ST Online

  • NTU launches new centre to develop innovative eye solutions

    Nanyang Technological University’s (NTU) latest research centre, the Ocular Therapeutic Engineering Centre (OTEC), was officially opened on 29 January 2013. Housed at NTU’s School of Materials Science and Engineering, the centre builds upon the school’s successful research collaboration with the Singapore Eye Research Institute (SERI). OTEC’s latest innovation is LipoLat, an anti-glaucoma drug wrapped in nano-sized capsules that is delivered by an injection into the outer layer in the front of the eye (conjunctiva). The nanocarrier will then slowly release the drug over several weeks. LipoLat is currently in clinical trials, and pre-clinical studies have shown that it is as effective at treating glaucoma as taking daily eye drops for up to three months.

    Reported in:
    - AsiaOne
    - Bio-Medicine
    - CNA Online
    - PhysOrg
    - Shin Min Daily News (Chinese)
    - ST Online
    - Today Online

  • SERI and NTU develop new gel to combat glaucoma
    post-op scars

    A gel designed by our team and SERI has proven effective in preventing further scarring in the eyes of patients who have undergone glaucoma surgery. It works by incorporating the drug into the gel and releasing the required drug over two days. A clinical trial has been conducted and it shown a 40 per cent drop in the number of injections needed for patients to prevent scarring after surgery.

    Reported in:
    - The Straits Times (page A4 and B1)
    - Straits Times Online
    - Channel News Asia
    - Channel 5 Video Clip